Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 428

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 428
---
 Capital.

Business Combination

Please see the section titled “ Proposal No. 1 — The Business Combination Proposal” for more information about the Merger Agreement.

| 233 |

Components of Operating Results

Revenue

Since inception, we have not generated any revenue and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our soft tissue reconstruction program is successful and results in regulatory approval, or if we entered into collaboration and license agreements with third parties, we may generate revenue from the combination of product sales or payments from collaboration or license agreements.

Research and Development Expenses

Research and development expenses consist of costs incurred in the development of our product candidates and primarily include:

| ● | expenses                                                     
 in connection with the development of our pipeline products; |

| ● | costs                                           
 of pre-clinical activities and clinical trials; |

| ● | costs                                                                                                                     
 of raw materials, as well as manufacturing costs of our materials, used in clinical trials and other development efforts; |

| ● | costs                    
 for consulting services; |

| ● | license                       
 fees and patent expenses; and |

| ● | costs                                  
 of regulatory submissions and reviews. |

We expense research and development costs as incurred.

Research and development costs are essential to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue clinical development or our product candidates. As products enter later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to fund our research and development expenses from our current cash and cash equivalents, any future equity or debt financings, or other capital sources, and through FutureTech once the Business Combination is consummated. We may also fund our research and development through potential collaborations with other companies or strategic transactions.

General and Administrative Expenses

General and administrative expenses consist primarily of professional fees for legal, accounting, tax, consulting services and insurance.

We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and initial commercialization of our product candidates.

Critical Accounting Policies

Our financial statements are prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”). The preparation of our financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as